Literature DB >> 2169577

Escherichia coli-derived envelope protein gD but not gC antigens of herpes simplex virus protect mice against a lethal challenge with HSV-1 and HSV-2.

M Bröker1, K J Abel, R Köhler, J Hilfenhaus, E Amann.   

Abstract

Immunization studies with HSV-1 and HSV-2 envelope proteins expressed in Escherichia coli were performed. After active immunization of mice with a gD-1 antigen (Leu53-Ala312) expressed as a fusion protein, the animals were protected from a lethal challenge with HSV-1 and HSV-2. In addition, antisera from rabbits immunized with the same gD-1 antigen also conferred passive immunity to mice against a challenge infection with either HSV-1 or HSV-2. In contrast to these successful gD-1 protection experiments, various gC-1 and gC-2 fusion proteins from E. coli failed to induce protective immunity. Moreover, the mice sera from immunized animals were not able to react with the authentic, glycosylated gC-1 and gC-2 envelope proteins, whereas sera raised against authentic gC-1 and gC-2 glycoproteins do recognize the gC fusion proteins from E. coli. These results indicate, that E. coli might represent an ideal system for expressing gD antigens as a possible component of a HSV vaccine, whereas gC antigen cannot be produced in an immunocompetent form in E. coli.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2169577     DOI: 10.1007/BF00202392

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  59 in total

1.  Passive immune protection by herpes simplex virus-specific monoclonal antibodies and monoclonal antibody-resistant mutants altered in pathogenicity.

Authors:  G Kümel; H C Kaerner; M Levine; C H Schröder; J C Glorioso
Journal:  J Virol       Date:  1985-12       Impact factor: 5.103

2.  Characterization of epitopes on native and denatured forms of herpes simplex virus glycoprotein B.

Authors:  J M Chapsal; L Pereira
Journal:  Virology       Date:  1988-06       Impact factor: 3.616

3.  Preparation and efficacy of antiherpes type 1 and 2 subunit vaccines.

Authors:  L Kavaklova; S Dundarov; P Andonov; B Bakalov; D Dundarova; I Brodvarova
Journal:  Acta Virol       Date:  1986-09       Impact factor: 1.162

4.  A novel glycoprotein for detection of herpes simplex virus type 1-specific antibodies.

Authors:  F K Lee; L Pereira; C Griffin; E Reid; A Nahmias
Journal:  J Virol Methods       Date:  1986-09       Impact factor: 2.014

5.  Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice.

Authors:  K J Cremer; M Mackett; C Wohlenberg; A L Notkins; B Moss
Journal:  Science       Date:  1985-05-10       Impact factor: 47.728

6.  Immunogenicity of subviral herpes simplex virus preparations. I. Formation of neutralizing antibodies in different animal species after administration of herpes simplex virus solubilized antigens.

Authors:  L Kutinová; V Slichtová; V Vonka
Journal:  Arch Virol       Date:  1979       Impact factor: 2.574

7.  Protection against herpes simplex virus infection in mice by Corynebacterium parvum.

Authors:  H Kirchner; H M Hirt; K Munk
Journal:  Infect Immun       Date:  1977-04       Impact factor: 3.441

8.  Extensive homology between the herpes simplex virus type 2 glycoprotein F gene and the herpes simplex virus type 1 glycoprotein C gene.

Authors:  D J Dowbenko; L A Lasky
Journal:  J Virol       Date:  1984-10       Impact factor: 5.103

9.  Detailed analysis of the portion of the herpes simplex virus type 1 genome encoding glycoprotein C.

Authors:  R J Frink; R Eisenberg; G Cohen; E K Wagner
Journal:  J Virol       Date:  1983-02       Impact factor: 5.103

10.  Type-common and type-specific monoclonal antibody to herpes simplex virus type 1.

Authors:  L Pereira; T Klassen; J R Baringer
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

View more
  2 in total

Review 1.  Developments in herpes simplex virus vaccines: old problems and new challenges.

Authors:  J Rajcáni; V Durmanová
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.629

2.  Immune response and cytokine production following immunization with experimental herpes simplex virus 1 (HSV-1) vaccines.

Authors:  V Durmanová; M Sapák; J Kosovský; I Rezuchová; M Kúdelová; M Buc; J Rajcáni
Journal:  Folia Microbiol (Praha)       Date:  2008-05-15       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.